Justus-Liebig-University of Giessen, Department of Rheumatology and Clinical Immunology, Kerckhoff-Klinik, Benekestr, Bad Nauheim, Germany.
Arthritis Res Ther. 2010;12(4):214. doi: 10.1186/ar3102. Epub 2010 Aug 24.
Due to ongoing developments of novel agents in the field of biological pharmacotherapy, there are now more arrows available in clinicians' quivers for the treatment of rheumatic conditions. As a consequence, however, clear treatment strategies have to be defined in order to guarantee a qualitatively high and individually stage-adapted, state-of-the-art regimen for affected patients. This review summarizes recent evidence regarding the rationale of using different biological therapies to treat rheumatoid arthritis, the most common inflammatory joint disorder after activated osteoarthritis, and draws an actual picture of a possible standardized therapeutic algorithm without claiming exclusive appropriateness.
由于生物药理学领域新型药物的不断发展,临床医生在治疗风湿性疾病时有了更多的选择。然而,为了确保为受影响的患者提供高质量、个体化和最新的治疗方案,必须明确治疗策略。这篇综述总结了最近关于使用不同生物疗法治疗类风湿关节炎的合理性的证据,类风湿关节炎是继骨关节炎之后最常见的炎性关节疾病,并描绘了一个可能的标准化治疗算法的实际图景,而不是声称其具有排他性的适用性。